- Essence : A Double-blind, Placebo-Controlled, Multicenter Study With and Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
- SRP4658-302 : Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy
Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen - SRP 4856-102: An open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients with DMD Amenable to Exon 51 Skipping
- SRP 4856-102-OLE: An Open-Label Safety, Tolerability, and Efficacy Study of Eteplirsen in Patients with Duchenne Muscular Dystrophy Who Have Completed Study 4658-102
- SRP4658-402: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
Acronym |
Essence |
SRP4658-302 |
SRP 4658-102 |
SRP 4856-102-OLE |
SRP4658-402 |
| Study type | BMR | BMR | BMR | BMR | BMR |
| Trial type | International multicentre trial | International multicentre trial | |||
| Intervention | Casimersen, Golodirsen and placebo | Casimersen, Golodirsen | Étéplirsen | Étéplirsen | Étéplirsen |
| Principal investigator |
Andreea Seferian | Andreea Seferian | Andreea Seferian | Andreea Seferian | Andreea Seferian |
| Sponsor | SAREPTA | SAREPTA | SAREPTA | SAREPTA | SAREPTA |
| Fundings | SAREPTA | SAREPTA | SAREPTA | SAREPTA | SAREPTA |
| Study status | Ongoing | In preparation | Ongoing | Ongoing | In preparation |
| Recruitment status | Ongoing | Ongoing | Ongoing | ||
| Population | Child | Child | Child | Child | Child |
| + infos on clinicaltrials.org | + infos on clinicaltrials.gov |
